Author

M. Rozenblit

Institutions: Yale Cancer Center, Yale University

Observed institutions: Yale Cancer Center, Yale University

OpenAlex ID: A5126270366

Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

2026 · E. L. Mayer, N. Graham, et al. · Clinical Cancer Research · 4

Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)

2026 · J. Chien, R. M. Mukhtar, et al. · Clinical Cancer Research · 1

Abstract PS5-08-07: Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer - HER2 PARADIGM trial

2026 · A. Kahn, J. Du, et al. · Clinical Cancer Research

Abstract PD4-07: Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study

2026 · E. Blondeaux, A. Meacci, et al. · Clinical Cancer Research

Abstract PD12-01: Surgical management of young BRCA1/2 carriers with early onset breast cancer

2026 · S. M. Wong, E. Blondeaux, et al. · Clinical Cancer Research

Abstract PS3-08-16: Real-world patterns of chemotherapy use in premenopausal women with node-negative early-stage HR+/HER2− breast cancer and intermediate genomic risk

2026 · I. Ajjawi, M. Wong, et al. · Clinical Cancer Research

Abstract PS5-09-06: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial

2026 · J. Du, W. Wei, et al. · Clinical Cancer Research

Abstract PS2-09-28: Use of DiviTum®TKa assay to assess CDK4/6 inhibitor medication compliance and drug interactions

2026 · M. Rozenblit, A. Kahn, et al. · Clinical Cancer Research

Abstract PS2-10-03: Impact of Circulating Tumor DNA (ctDNA) monitoring on Patient Anxiety and Clinician Decision-Making in Early-Stage Breast Cancer (PACE-ctDNA)

2026 · D. Isseroff, N. Wiesendanger, et al. · Clinical Cancer Research

Works count: 9

Citation count: 5

H-index: 1

I10-index: